Literature DB >> 29194687

Serum-free complete medium, an alternative medium to mimic androgen deprivation in human prostate cancer cell line models.

Michael V Fiandalo1, John H Wilton1,2, Krystin M Mantione2, Carol Wrzosek1, Kristopher M Attwood3, Yue Wu1, James L Mohler1.   

Abstract

BACKGROUND: Almost all men who present with advanced prostate cancer (CaP) and some men who fail therapy for clinically localized CaP are treated with androgen deprivation therapy (ADT). CaP cell lines are used to identify and characterize new agents for ADT or investigate mechanisms of ADT resistance. CaP cell lines are maintained in culture medium that contains fetal bovine serum, which contains testosterone (T). Androgen deprivation experiments are performed using media supplemented with androgen-free serum, such as charcoal stripped fetal bovine serum (CS-FBS). However, CS-FBS composition varies from batch-to-batch and variations may impact experimental reproducibility. Serum free media (SFM) may provide a better defined alternative to media supplemented with CS-FBS (CSM).
METHODS: Cell growth of six human CaP cell lines was assessed using 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). Androgen levels were measured using liquid chromatography-tandem mass spectrometry (LC-MS/MS).
RESULTS: MTT assays showed 5 of 6 CaP cell lines grew after 6 days of culture in androgen- deprived SFM or CSM. LNCaP and VCaP growth was stimulated when cells were cultured in SFM or CSM supplemented with T. LNCaP, C4-2, LAPC-4, and VCaP cell growth was inhibited when cultured in SFM or CSM with T and bicalutamide. LC-MS/MS data showed LAPC-4 cells produced similar DHT levels when cultured in T-supplemented SFM or CSM. Dutasteride impaired T to DHT metabolism in LAPC-4.
CONCLUSIONS: Media composition contributed to growth differences observed between CaP cells cultured in SFM or CSM. However, the differences in media composition did not impair CaP cell response to T-stimulated growth, bicalutamide growth inhibition, metabolism of T, or dutasteride efficiency. SFM can be used as a better defined alternative to CSM for androgen deprivation experiments.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  DHT; androgen deprivation; charcoal-stripped media; mass spectrometry; prostate cancer

Mesh:

Substances:

Year:  2017        PMID: 29194687      PMCID: PMC5768451          DOI: 10.1002/pros.23459

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  16 in total

1.  Androgenic biomarker prof|ling in human matrices and cell culture samples using high throughput, electrospray tandem mass spectrometry.

Authors:  John H Wilton; Mark A Titus; Eleni Efstathiou; Gerald J Fetterly; James L Mohler
Journal:  Prostate       Date:  2014-05       Impact factor: 4.104

2.  Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer.

Authors:  Mark A Titus; Michael J Schell; Fred B Lih; Kenneth B Tomer; James L Mohler
Journal:  Clin Cancer Res       Date:  2005-07-01       Impact factor: 12.531

3.  Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice.

Authors:  K A Klein; R E Reiter; J Redula; H Moradi; X L Zhu; A R Brothman; D J Lamb; M Marcelli; A Belldegrun; O N Witte; C L Sawyers
Journal:  Nat Med       Date:  1997-04       Impact factor: 53.440

4.  Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer.

Authors:  James L Mohler; Mark A Titus; Suxia Bai; Brian J Kennerley; Fred B Lih; Kenneth B Tomer; Elizabeth M Wilson
Journal:  Cancer Res       Date:  2011-02-08       Impact factor: 12.701

5.  Androgen deprivation induces rapid involution and recovery of human prostate vasculature.

Authors:  Alejandro Godoy; Viviana P Montecinos; Danny R Gray; Paula Sotomayor; Jeffrey M Yau; R Robert Vethanayagam; Swaroop Singh; James L Mohler; Gary J Smith
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-08-10       Impact factor: 4.310

6.  Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells.

Authors:  H C Wu; J T Hsieh; M E Gleave; N M Brown; S Pathak; L W Chung
Journal:  Int J Cancer       Date:  1994-05-01       Impact factor: 7.396

7.  Effects of resin or charcoal treatment on fetal bovine serum and bovine calf serum.

Authors:  Zhimin Cao; Clint West; Carol S Norton-Wenzel; Robert Rej; Faith B Davis; Paul J Davis; Robert Rej
Journal:  Endocr Res       Date:  2009       Impact factor: 1.720

8.  Prostate cancer cells differ in testosterone accumulation, dihydrotestosterone conversion, and androgen receptor signaling response to steroid 5α-reductase inhibitors.

Authors:  Yue Wu; Alejandro Godoy; Faris Azzouni; John H Wilton; Clement Ip; James L Mohler
Journal:  Prostate       Date:  2013-06-27       Impact factor: 4.104

9.  Tissue culture media supplemented with 10% fetal calf serum contains a castrate level of testosterone.

Authors:  J P Michiel Sedelaar; John T Isaacs
Journal:  Prostate       Date:  2009-12-01       Impact factor: 4.104

10.  Human-derived alternatives to fetal bovine serum in cell culture.

Authors:  Karin Witzeneder; Andrea Lindenmair; Christian Gabriel; Katharina Höller; Denise Theiß; Heinz Redl; Simone Hennerbichler
Journal:  Transfus Med Hemother       Date:  2013-11-29       Impact factor: 3.747

View more
  3 in total

1.  Adrenal androgens rescue prostatic dihydrotestosterone production and growth of prostate cancer cells after castration.

Authors:  Yue Wu; Li Tang; Gissou Azabdaftari; Elena Pop; Gary J Smith
Journal:  Mol Cell Endocrinol       Date:  2019-02-23       Impact factor: 4.102

2.  SLX4IP Promotes Telomere Maintenance in Androgen Receptor-Independent Castration-Resistant Prostate Cancer through ALT-like Telomeric PML Localization.

Authors:  Tawna L Mangosh; Wisam N Awadallah; Magdalena M Grabowska; Derek J Taylor
Journal:  Mol Cancer Res       Date:  2020-11-13       Impact factor: 6.333

3.  Recapitulation of prostate tissue cell type-specific transcriptomes by an in vivo primary prostate tissue xenograft model.

Authors:  Nelson T Gross; Jianmin Wang; Michael V Fiandalo; Eduardo Cortes Gomez; Anica Watts; Alejandro S Godoy; Gary J Smith; Yue Wu
Journal:  PLoS One       Date:  2020-06-25       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.